{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T03:21:28Z","timestamp":1789269688586,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008967","name":"Philipps-Universit\u00e4t Marburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008967","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Apalutamide plus androgen-deprivation therapy (ADT) improved outcomes in patients with non-metastatic castration-resistant prostate cancer (nmCRPC). Nevertheless real-world data are limited. The aim of this multicenter study was to generate real-world data from nmCRPC patients treated with ADT plus apalutamide.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this observational cohort based investigator initiated trial data of nmCRPC patients receiving apalutamide plus ADT were collected focusing on patient demographic data, prostate-specific antigen (PSA) declines, safety profile including dose modification\/discontinuation as well as subsequent therapy and metastasis-free survival (MFS).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Data from a total of 31 nmCRPC patients were documented. Compared to the Phase III study Spartan real-world patients are older, showed a higher ECOG-PS and more aggressive tumors. <jats:bold><jats:italic>In the cohort<\/jats:italic><\/jats:bold> PSA decreased about 98.1%, <jats:bold><jats:italic>74%<\/jats:italic><\/jats:bold> of patients showed a PSA decrease <jats:bold><jats:italic>over 90%<\/jats:italic><\/jats:bold> and 54.8% reached a PSA-level\u2009&lt;\u20090.2ng\/ml. Apalutamide was well tolerated in real world patients: adverse events occurred in 67.7% but were in the majority mild (\u2265\u2009grade 3: 6.5%). Dose reduction was necessary in 38.7% and 32.2% discontinued apalutamide treatment. MFS was 43 months and majority of patients were subsequently treated with abiraterone.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In real world more comorbid nmCRPC patients with a higher ECOG-PS and more aggressive tumors are treated with apalutamide plus ADT. Nevertheless efficacy results as well as side effects are similar in real-world compared to Spartan trial showing also a rapid, durable and deep PSA response with a median MFS of 43 months.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-024-05928-7","type":"journal-article","created":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T06:02:20Z","timestamp":1725861740000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Apalutamide for non-metastatic castration-resistant prostate cancer (nmCRPC): real world data of a multicenter study"],"prefix":"10.1007","volume":"150","author":[{"given":"Axel","family":"Hegele","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"H\u00e4u\u00dfermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Schultheis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lennart","family":"Skrobek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meike","family":"Vink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Hollwegs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Huwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Maywurm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Bartsch-Polle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jost","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Thiemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denny","family":"Varughese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,9]]},"reference":[{"key":"5928_CR1","doi-asserted-by":"publisher","unstructured":"Baboudjian M, Gauth\u00e9 M, Barret E, Brureau L, Rocchi P, Cr\u00e9hange G, Dariane C, Fiard G, Fromont G, Beauval JB, Mathieu R, Renard-Penna R, Roubaud G, Ruffion A, Sargos P, Roupr\u00eat M, Ploussard G (2022) How PET-CT is Changing the Management of Non-metastatic Castration-resistant Prostate Cancer? Comment la TEP-TDM Peut Modifier la Prise en Charge du Cancer de la Prostate Non M\u00e9tastatique R\u00e9sistant \u00e0 la Castration ? Prog Urol 32:6S43-6S53. https:\/\/doi.org\/10.1016\/S1166-7087(22)00174-9","DOI":"10.1016\/S1166-7087(22)00174-9"},{"key":"5928_CR2","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1002\/pds.4932","volume":"29","author":"E Baumfeld Andre","year":"2020","unstructured":"Baumfeld Andre E, Reynolds R, Caubel P, Azoulay L, Dreyer NA (2020) Trial designs using real-world data: the changing landscape of the regulatory approval process. Pharmacoepidemiol Drug Saf 29:1201\u20131212. https:\/\/doi.org\/10.1002\/pds.4932","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"5928_CR3","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1158\/0008-5472.CAN-11-3948","volume":"72","author":"NJ Clegg","year":"2012","unstructured":"Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, Chen Y, Grillot K, Bischoff ED, Cai L, Aparicio A, Dorow S, Arora V, Shao G, Qian J, Zhao H, Yang G, Cao C, Sensintaffar J, Wasielewska T, Herbert MR, Bonnefous C, Darimont B, Scher HI, Smith-Jones P, Klang M, Smith ND, De Stanchina E, Wu N, Ouerfelli O, Rix PJ, Heyman RA, Jung ME, Sawyers CL, Hager JH (2012) ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res 72:1494\u20131503. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-3948","journal-title":"Cancer Res"},{"key":"5928_CR4","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3390\/cancers9060067","volume":"9","author":"DJ Crona","year":"2017","unstructured":"Crona DJ, Whang YE (2017) Androgen receptor-dependent and -independent mechanisms involved in prostate Cancer Therapy Resistance. Cancers (Basel) 9:67. https:\/\/doi.org\/10.3390\/cancers9060067","journal-title":"Cancers (Basel)"},{"key":"5928_CR5","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s00345-020-03139-6","volume":"38","author":"P Dahm","year":"2020","unstructured":"Dahm P, Kunath F (2020) Evidence-based medicine in urology. World J Urol 38:515\u2013516. https:\/\/doi.org\/10.1007\/s00345-020-03139-6","journal-title":"World J Urol"},{"key":"5928_CR6","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1002\/cpt.2083","volume":"109","author":"HG Eichler","year":"2021","unstructured":"Eichler HG, Pignatti F, Schwarzer-Daum B, Hidalgo-Simon A, Eichler I, Arlett P, Humphreys A, Vamvakas S, Brun N, Rasi G (2021) Randomized controlled trials Versus Real World evidence: neither Magic nor myth. Clin Pharmacol Ther 109:1212\u20131218. https:\/\/doi.org\/10.1002\/cpt.2083","journal-title":"Clin Pharmacol Ther"},{"key":"5928_CR7","doi-asserted-by":"publisher","first-page":"7448","DOI":"10.1158\/1078-0432.CCR-19-1050","volume":"25","author":"WP Fendler","year":"2019","unstructured":"Fendler WP, Weber M, Iravani A, Hofman MS, Calais J, Czernin J, Ilhan H, Saad F, Small EJ, Smith MR, Perez PM, Hope TA, Rauscher I, Londhe A, Lopez-Gitlitz A, Cheng S, Maurer T, Herrmann K, Eiber M, Hadaschik B (2019) Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer. Clin Cancer Res 25:7448\u20137454. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1050","journal-title":"Clin Cancer Res"},{"key":"5928_CR8","doi-asserted-by":"crossref","unstructured":"Gartrell BA, Coleman R, Efstathiou E, Fizazi K, Logothetis CJ, Smith MR, Sonpavde G, Sartor O, Saad F (2015) Metastatic prostate Cancer and the bone. Significance and Therapeutic Options. Eur Urol 68:850-858. doi:10.1016\/j.eururo.2015.06.039","DOI":"10.1016\/j.eururo.2015.06.039"},{"key":"5928_CR10","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1186\/s12885-022-09364-z","volume":"22","author":"A Hussain","year":"2022","unstructured":"Hussain A, Jiang S, Varghese D, Appukkuttan S, Kebede N, Gnanasakthy K, Macahilig C, Waldeck R, Corman S (2022) Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States. BMC Cancer 22:304. https:\/\/doi.org\/10.1186\/s12885-022-09364-z","journal-title":"BMC Cancer"},{"key":"5928_CR11","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/1346-8138.16972","volume":"51","author":"M Katsuta","year":"2024","unstructured":"Katsuta M, Nobeyama Y, Hirafuku K, Tashiro K, Kimura T, Asahina A (2024) Characteristics of mild and severe apalutamide-related cutaneous adverse events in patients with prostate cancer: a review of the literature. J Dermatol 51:110\u2013114. https:\/\/doi.org\/10.1111\/1346-8138.16972","journal-title":"J Dermatol"},{"key":"5928_CR12","doi-asserted-by":"publisher","first-page":"e13592","DOI":"10.1111\/ecc.13592","volume":"31","author":"U R\u00f6nning\u00e5s","year":"2022","unstructured":"R\u00f6nning\u00e5s U, Holm M, Doveson S, Fransson P, Beckman L, Wennman-Larsen A (2022) Signs and symptoms in relation to progression, experiences of an uncertain illness situation in men with metastatic castration-resistant prostate cancer-A qualitative study. Eur J Cancer Care 31:e13592. https:\/\/doi.org\/10.1111\/ecc.13592","journal-title":"Eur J Cancer Care"},{"key":"5928_CR13","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.eururo.2021.11.020","volume":"81","author":"F Saad","year":"2022","unstructured":"Saad F, Small EJ, Feng FY, Graff JN, Olmos D, Hadaschik BA, Oudard S, Londhe A, Bhaumik A, Lopez-Gitlitz A, Thomas S, Mundle SD, Chowdhury S, Smith MR (2022) Deep prostate-specific Antigen response following addition of apalutamide to Ongoing Androgen Deprivation Therapy and Long-Term Clinical Benefit in SPARTAN. Eur Urol 81:184\u2013192. https:\/\/doi.org\/10.1016\/j.eururo.2021.11.020","journal-title":"Eur Urol"},{"key":"5928_CR14","doi-asserted-by":"publisher","first-page":"21969","DOI":"10.1002\/cam4.6769","volume":"12","author":"JC S\u00e1nchez","year":"2023","unstructured":"S\u00e1nchez JC, Picola N, Rodriguez-Vida A, Costa M, Casta\u00f1eda DM, M\u00e1rquez MP, Rodriguez JM, Gaya JM, Bravo A, Buisan O, Servian P, Suarez JF, Felip MM, Caparr\u00f3s MJR, Asensio AA, Vilaseca A (2023) Apalutamide for prostate cancer: Multicentre and multidisciplinary real-world study of 227 patients. Cancer Med 12:21969\u201321977. https:\/\/doi.org\/10.1002\/cam4.6769","journal-title":"Cancer Med"},{"key":"5928_CR15","doi-asserted-by":"publisher","first-page":"10159","DOI":"10.3390\/ijerph191610159","volume":"19","author":"F Schad","year":"2022","unstructured":"Schad F, Thronicke A (2022) Real-world evidence-current developments and perspectives. Int J Environ Res Public Health 19:10159. https:\/\/doi.org\/10.3390\/ijerph191610159","journal-title":"Int J Environ Res Public Health"},{"key":"5928_CR16","doi-asserted-by":"publisher","first-page":"e0139440","DOI":"10.1371\/journal.pone.0139440","volume":"10","author":"HI Scher","year":"2015","unstructured":"Scher HI, Solo K, Valant J, Todd MB, Mehra M (2015) Prevalence of prostate cancer clinical states and mortality in the United States: estimates using a dynamic progression model. PLoS ONE 10:e0139440\u2013e0139440. https:\/\/doi.org\/10.1371\/journal.pone.0139440","journal-title":"PLoS ONE"},{"key":"5928_CR17","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1200\/JCO.2005.01.529","volume":"23","author":"MR Smith","year":"2005","unstructured":"Smith MR, Kabbinavar F, Saad F, Hussain A, Gittelman MC, Bilhartz DL, Wynne C, Murray R, Zinner NR, Schulman C, Linnartz R, Zheng M, Goessl C, Hei YJ, Small EJ, Cook R, Higano CS (2005) Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 23:2918\u20132925. https:\/\/doi.org\/10.1200\/JCO.2005.01.529","journal-title":"J Clin Oncol"},{"key":"5928_CR18","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1002\/cncr.25762","volume":"117","author":"MR Smith","year":"2011","unstructured":"Smith MR, Cook R, Lee KA, Nelson JB (2011) Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer. Cancer 117:2077\u20132085. https:\/\/doi.org\/10.1002\/cncr.25762","journal-title":"Cancer"},{"key":"5928_CR19","doi-asserted-by":"publisher","first-page":"3800","DOI":"10.1200\/JCO.2012.44.6716","volume":"31","author":"MR Smith","year":"2013","unstructured":"Smith MR, Saad F, Oudard S, Shore N, Fizazi K, Sieber P, Tombal B, Damiao R, Marx G, Miller K, Van Veldhuizen P, Morote J, Ye Z, Dansey R, Goessl C (2013) Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol 31:3800\u20133806. https:\/\/doi.org\/10.1200\/JCO.2012.44.6716","journal-title":"J Clin Oncol"},{"key":"5928_CR20","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","volume":"378","author":"MR Smith","year":"2018","unstructured":"Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Gitlitz A, Trudel GC, Espina BM, Shu Y, Park YC, Rackoff WR, Yu MK, Small EJ, SPARTAN Investigators (2018) Apalutamide Treatment and Metastasis-free survival in prostate Cancer. N Engl J Med 378:1408\u20131418. https:\/\/doi.org\/10.1056\/NEJMoa1715546","journal-title":"N Engl J Med"},{"key":"5928_CR21","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.eururo.2020.08.011","volume":"79","author":"MR Smith","year":"2021","unstructured":"Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, De Porre P, Smith AA, Brookman-May SD, Li S, Zhang K, Rooney B, Lopez-Gitlitz A, Small EJ (2021) Apalutamide and overall survival in prostate Cancer. Eur Urol 79:150\u2013158. https:\/\/doi.org\/10.1016\/j.eururo.2020.08.011","journal-title":"Eur Urol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05928-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-024-05928-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05928-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T15:15:13Z","timestamp":1728486913000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-024-05928-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,9]]},"references-count":20,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["5928"],"URL":"https:\/\/doi.org\/10.1007\/s00432-024-05928-7","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,9]]},"assertion":[{"value":"31 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors did not receive support from any organization for the submitted work. Axel Hegele has received speaker and consultant honoraria from Janssen (Germany) and served on advisory boards for Janssen (Germany). All other authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"414"}}